Screener
Veradermics MANE CapEx
CapEx at other companies
Other financials
Where this comes from
Reported directly by Veradermics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Veradermics’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 5:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001827635-26-000019
| (in thousands) | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Other current liabilities and lease liabilities | (8) | (7) |
| Net cash used in operating activities | (21,168) | (13,317) |
| Cash flows from investing activities: | ||
| Purchase of property, plant and equipment | — | (19) |
| Purchases of marketable securities | (122,988) | (15,731) |
| Maturities of marketable securities | 21,689 | — |
| Net cash used in investing activities | (101,299) | (15,750) |
| Cash flows from financing activities: |
Item 1. Condensed Consolidated Financial Statements (
FAQ
- What is Veradermics's capex?
- Veradermics (MANE) reported capex of $0 in Q1 2026.
- How has Veradermics's capex changed year-over-year?
- Veradermics's capex decreased by 100.0% year-over-year, from $19K to $0.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Veradermics's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude